Effects of intensive blood-pressure control in type 2 diabetes mellitus

New England Journal of Medicine

Volumn 362, Issue 17, 2010, Pages 1575-1585

  Cushman, William C ^a   Evans, Gregory W ^b   Byington, Robert P ^b   Goff Jr , David C ^b   Grimm Jr , Richard H ^c   Cutler, Jeffrey A ^d   Simons Morton, Denise G ^d   Basile, Jan N ^e   Corson, Marshall A ^f   Probstfield, Jeffrey L ^f   Katz, Lois ^g   Peterson, Kevin A ^c   Friedewald, William T ^g   Buse, John B ⁱ   Bigger, J Thomas ^h   Gerstein, Hertzel C ^j   Ismail Beigi, Faramarz ^k  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g Columbia University Mailman School of Public Health ^*  (United States)

^h Columbia University College of Physicians and Surgeons ^*  (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^j MCMASTER UNIVERSITY   (Canada)

^k CASE WESTERN RESERVE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ADVERSE OUTCOME; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DIALYSIS; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STROKE; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 77951735232     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1001286     Document Type: Article

References (17)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12 yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444 (Pubitemid 23046633)
2. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-419 (Pubitemid 30609443)
3. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572 [Erratum, JAMA 2003;290:197.]
4. Cushman WC, Grimm RH Jr, Cutler JA, et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:Suppl:44i-55i.
5. ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99:Suppl:21i-33i.
6. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
7. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574
8. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995;123:754-762
9. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254 [Erratum, Ann Intern Med 2008;149:519.] (Pubitemid 46768608)
10. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer-Verlag, 2000.
11. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-774
12. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: metaanalysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
13. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713 [Erratum, BMJ 1999;318:29.]
14. Idem. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-720
15. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-1762 (Pubitemid 28269185)
16. Zanchetti A, Hansson L, Clement D, et al. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 2003;21:797-804.
17. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perin dopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-840 (Pubitemid 47362321)